ArticleInternational journal of clinical and experimental pathology2015
Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Pediatric and Adult Sinonasal Phosphaturic Mesenchymal Tumors: CDKN2A Copy Number Alterations and Their Association with Recurrence.Head and neck pathology · 2026Article
- Recent research progress on the etiology and pathogenesis of tumor-induced osteomalacia: A review.Journal of bone oncology · 2026Review
- Case Report: Phosphaturic mesenchymal tumor presenting solely as knee pain without hypophosphatemia.Frontiers in oncology · 2025Article
- A 50-Year-Old Man Presenting with Multiple Bone Lesions and a Diagnosis of Phosphaturic Mesenchymal Tumor of the Femur.The American journal of case reports · 2024Article
- Ovarian Teratoma Causing Oncogenic Osteomalacia: An Instance of Serendipity.Journal of obstetrics and gynaecology of India · 2022Article
- Soft Tissue Special Issue: Giant Cell-Rich Lesions of the Head and Neck Region.Head and neck pathology · 2020Review
- What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.Virchows Archiv : an international journal of pathology · 2020Review
- Phosphaturic mesenchymal tumors among elderly patients: a case report and review of literature.Endocrinology, diabetes & metabolism case reports · 2019Article
- Tumor-induced osteomalacia.Osteoporosis and sarcopenia · 2018Review
- Phosphaturic mesenchymal tumor and related wound problem.Medicine · 2018Review
- Fibronectin 1 (Cancer genomics & proteomicsReview
- Phosphaturic mesenchymal tumor in right thigh: 2 cases report and literature review.Clinical pathology (Thousand Oaks, Ventura County, Calif.)Article
- An Update on Selected Giant Cell-Rich Tumors of Soft Tissue.Cancer genomics & proteomicsReview
- Chondromyxoid Fibroma: An Updated Review.In vivo (Athens, Greece)Review
- Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss.Autopsy & case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphaturic mesenchymal tumor (PMT) has been elucidated as a cause of tumor-induced osteomalacia (TIO) associated with mesenchymal neoplasm. TIO is associated with the production of phosphatonins, such as fibroblast growth factor 23 (FGF23), which participate in phosphate homeostasis. Fibroblast growth factor receptor 1 (FGFR1) is a known receptor of FGF23, and it was recently found that the fibronectin 1 (FN1)-FGFR1 fusion gene is present in 60% of PMT cases. Immunohistochemical evaluation of FGFR1 expression in PMT has not been reported till date. We analyzed 11 cases of PMT in this study and found that 36% of cases (4/11 cases) exhibited cytoplasmic and membranous staining with strong intensity, and 64% of cases (7/11 cases) exhibited cytoplasmic dot-like staining with moderate to weak intensity. The aforementioned 36% of cases may reflect the presence of the FN1-FGFR1 fusion gene, as the FN1 promoter enhances FGFR1 expression. Although FGFR1 signaling increases FGF23 expression in an autocrine/paracrine loop, FGF23 serum level does not correlate with FGFR1 membranous expression (staining with strong intensity). Thus, we speculate that important factors other than FGFR1 are involved in the tumor biology of PMTs overexpressing FGF23.
Indexed as
Identifiers
26464698PMC4583930W2246104799What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.